Our stories
Some subtypes of gastric/oesophageal adenocarcinoma responsive to immunotherapy
Interview with medical oncologist and Oncode Investigator Dr Sarah Derks. Gastric and oesophageal adenocarcinomas are a heterogeneous group, so it should come as no surprise that not all subtypes of gastric and oesophageal adenocarcinoma respond equally well to immunotherapy. Sarah explains why tumours that test positive for the Epstein-Barr virus and tumours with microsatellite instability are particularly responsive to immune checkpoint inhibitors.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Edwin Cuppen discusses tumour-agnostic drugs for cancer patients
Cancer medicine has traditionally focused on the site of a tumour, but in recent decades research has held out the promise of spotlighting its genetic background instead. The ultimate goal is to achieve more personalised treatment. Now that the first ‘tumour-agnostic drug’ has been authorised, that moment has finally arrived.
“We have underestimated the complexity of cancer.”
Anton Berns doesn’t sound like someone who is about to stop working. The 74 years old professor in Molecular Genetics talks with great enthusiasm about new technologies which, according to him, will drive the progress in cancer research the coming years.
Open Science: quicker access and more transparency
Oncode Investigator Bas van Steensel (NKI), is one of the Open Science advocates within Oncode Institute. Not a topic that is high on everyone's priority list, but that makes Bas extra passionate to explain the importance of it, and – not in the least – why researchers can benefit from it.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Why clinicians and fundamental researchers need each other
Oncode Investigator Wilbert Zwart and Medical Oncologist André Bergman are interviewed why clinicians and fundamental researchers need each other, and the value produced by such collaboration
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
The Oncode Community Platform: Connecting researchers to create impact
Oncode Institute is a mission-driven research effort that goes beyond the competitive model of science. Within Oncode, researchers are strongly encouraged to work together because we need all available talent to outsmart cancer and impact patient’s lives. Oncode has co-created a digital tool with the research community that should help researchers find the expertise they need.
Annual Conference – young researchers are the future
On November 8th and 9th 2018, cancer researchers from all over The Netherlands gathered for the Oncode-CGC Annual Conference. A quick look at the audience showed that not only the speakers were a dynamic mix of people. It is safe to say that the cancer research community is young, diverse and very motivated to create impact.
ElizeBrolsma
<span>Elize</span><span>Brolsma</span>
Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations.
At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Medications specifically for Children with Cancer
Separate research is needed in the case of children with cancer. Children differ from adults in the types of cancer they develop. Researchers at the recently opened Princess Máxima Centre for Pediatric Oncology are looking for medications that work more specific than chemotherapy. NEMO Kennislink visited them.
Scroll for more
- 1
- 2